TY - JOUR
T1 - Family History and Risk of Ovarian Cancer
AU - Trimble, Edward L.
AU - Seltzer, Vicki L.
PY - 1995/8/2
Y1 - 1995/8/2
N2 - Drs Foulkes and colleagues underscore a key point in the recommendations of the NIH Consensus Development Panel on Ovarian Cancer, namely, the importance of ascertaining family history to define a woman's inherited risk of ovarian, breast, colon, and other cancers. However, it is important to differentiate between those women whose pedigree fits one of the three major syndromes (site-specific ovarian cancer syndrome, breast-ovarian cancer syndrome, and Lynch II syndrome) and those in whom the appearance of ovarian cancer appears to be sporadic.1The vast majority (97%) of women with two or three relatives with ovarian cancer will not have a hereditary cancer syndrome.2,3Their lifetime probability of developing ovarian cancer appears to be about 7%. Those women whose family history is consistent with a hereditary cancer syndrome may have a lifetime risk of 40%, assuming an autosomal-dominant inheritance pattern with 80% penetrance.4The development of.
AB - Drs Foulkes and colleagues underscore a key point in the recommendations of the NIH Consensus Development Panel on Ovarian Cancer, namely, the importance of ascertaining family history to define a woman's inherited risk of ovarian, breast, colon, and other cancers. However, it is important to differentiate between those women whose pedigree fits one of the three major syndromes (site-specific ovarian cancer syndrome, breast-ovarian cancer syndrome, and Lynch II syndrome) and those in whom the appearance of ovarian cancer appears to be sporadic.1The vast majority (97%) of women with two or three relatives with ovarian cancer will not have a hereditary cancer syndrome.2,3Their lifetime probability of developing ovarian cancer appears to be about 7%. Those women whose family history is consistent with a hereditary cancer syndrome may have a lifetime risk of 40%, assuming an autosomal-dominant inheritance pattern with 80% penetrance.4The development of.
UR - http://www.scopus.com/inward/record.url?scp=84942480712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942480712&partnerID=8YFLogxK
U2 - 10.1001/jama.1995.03530050031023
DO - 10.1001/jama.1995.03530050031023
M3 - Letter
AN - SCOPUS:84942480712
SN - 0098-7484
VL - 274
JO - JAMA: The Journal of the American Medical Association
JF - JAMA: The Journal of the American Medical Association
IS - 5
ER -